---
layout: post
title: 'New Drug Approvals 2012 - Pt. XXIII - Omacetaxine mepesuccinate (SYNRIBOTM) '
date: '2012-11-04T09:03:00.000Z'
author: Bissan Al-Lazikani
tags:
- Natural Product Drugs
- Parenteral Drugs
- 2012 New Drugs
modified_time: '2012-11-05T23:01:06.603Z'
thumbnail: http://3.bp.blogspot.com/-9e0sHLgB69s/UJYz4D597XI/AAAAAAAACVQ/ZIIDznf33tU/s72-c/ht_121029_teva_synribo_200x151.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-2720437691628697936
blogger_orig_url: http://chembl.blogspot.com/2012/11/new-drug-approvals-2012-pt-xxiii.html
---

<center>
<a href="http://3.bp.blogspot.com/-9e0sHLgB69s/UJYz4D597XI/AAAAAAAACVQ/ZIIDznf33tU/s1600/ht_121029_teva_synribo_200x151.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://3.bp.blogspot.com/-9e0sHLgB69s/UJYz4D597XI/AAAAAAAACVQ/ZIIDznf33tU/s1600/ht_121029_teva_synribo_200x151.jpg" /></a></center>
<center>
</center>
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/7,0,0,0,1,0,1,0,0" width="400" /><br />


<br />
<b>ATC code:&nbsp;</b>L01XX40<br />
<b>Wikipedia: </b><a href="http://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate">Omacetaxine_mepesuccinate</a><br />


<br />
</center>
<center style="text-align: left;">
On October 22nd 2012 the FDA approved omacetaxine mepesuccinate (research code: CGX-635, trivial name: Homoharringtonine, trademark: Synribo<sup>TM</sup>) for the treatment of chronic or accelerated phase chronic myeloid leukaemia (<a href="http://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia">CML</a>) in adults with resistance to two or more tyrosine kinase inhibitors.&nbsp;Omacetaxine is an old drug identified 35 years ago and known to have activity in CML, but its clinical development was previously halted due to the discovery of BCL-ABL and other targeted kinase inhibitors <a href="http://www.ncbi.nlm.nih.gov/pubmed/21294709">Pubmed:&nbsp;21294709</a>.&nbsp;The rapid development of tyrosine kinase inhibitor resistant tumors has led to the need for agents that can act in these treatment-derived drug-resistant patients.&nbsp;Omacetaxine mepesuccinate has been approved based on observed&nbsp;major cytogenetic response rather than on improvement in disease-related symptoms or increased survival.</center>
<br />
<div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-Oqf_j9EdMiw/UJYjz7nmpoI/AAAAAAAAAK4/_mnmrV9uWpM/s1600/Omacetaxine.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="201" src="http://2.bp.blogspot.com/-Oqf_j9EdMiw/UJYjz7nmpoI/AAAAAAAAAK4/_mnmrV9uWpM/s320/Omacetaxine.png" width="272" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Omacetaxine mepesuccinate/homoharringtonine is&nbsp;a cephalotaxine ester of prepared by a semi-synthetic process from cephalotaxine, an extract from the leaves of <i>Cephalotaxus sp </i>found in Southern China. Its molecular formula is C29H39NO9, with an IUPAC name of&nbsp;4-methyl (2<span style="font-style: italic;">R</span>)-hydroxyl-2-(4-hydroxyl-4-methylpentyl) butanedioate,&nbsp;its molecular weight is 545.6 Da.&nbsp;It is absorbed following subcutaneous administration, and maximum plasma (Tmax) concentrations are achieved after ~30 minutes. The volume of distribution (Vd) is variable at 141 +/- 93.4 L following subcutaneous administration of 1.25 mg/m<sup>2</sup> twice daily for 11 days.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
The mechanistic target of&nbsp;omacetaxine mepesuccinate is not fully known, however its action includes inhibition of protein synthesis. It was found to bind to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit in archaeabacteria and is understood to prevent the correct positioning of amino acid side chains of incoming aminoacyl-tRNAs, thus inhibiting the elongation step of peptide synthesis.&nbsp;</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
It was shown in vitro to reduce the protein levels of a number of oncogenic proteins including BCR-ABL and MCL1. Because it does not bind BRC-ABL directly, it is active both in wild-type and resistant tumours harbouring the ABL drug resistance mutant: T351I as seen in mouse models.</div>
<div class="separator" style="clear: both; text-align: left;">
<br /></div>
<div class="separator" style="clear: both; text-align: left;">
Prescribing information is <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203585lbl.pdf">here</a></div>
<br />
<span style="text-align: left;">Synribo</span><sup style="text-align: left;">TM&nbsp;</sup><span style="text-align: left;">is marketed by IVAX pharmaceuticals</span></div>
